Third Pole Therapeutics

Each year, roughly 100,000 babies worldwide are diagnosed with a life-threatening condition called persistent pulmonary hypertension of the newborn (PPHN). In infants with PPHN, blood does not circulate properly through the lungs, and sufficient oxygen does not reach the heart, brain and other major organs. Yet, despite the proven effectiveness of inhaled nitric oxide (iNO) as a life-saving treatment for PPHN, access to it by patients has been severely limited—in part because of its expensive, unwieldy system of delivery…

The technologies that improve lives in the world’s underserved communities are born as prototypes that evolve through testing and tinkering in workshops, laboratories and garages…

A new device, the Third Pole is able to generate nitric oxide (NO) from the air that can help improve oxygenation and treat pulmonary hypertension a common problem among some newborns…

The Third Pole makes its own nitric oxide to treat pulmonary hypertension,
no tanks required….

Inhaled nitric oxide (iNO) relaxes blood vessels in the lungs and is an important and life-saving treatment for pulmonary hypertension. Current iNO delivery solutions are estimated to cost $2,800 per day and rely on compressed gas delivery which limits accessibility and applicability of this technology worldwide…

Third Pole has won a Johnson & Johnson Innovation award for a lighter device that provides an unlimited supply of nitric oxide (NO) to patients with pulmonary hypertension (PH) and other respiratory conditions…

In the 25 years since discovering a life-saving therapy consisting of breathing low levels of the gas nitric oxide—which is still the only selective inhaled pulmonary vasodilator—Massachusetts General Hospital (MGH) anesthesiologist Warren M. Zapol, MD, and his MGH team has given clinicians a treatment to simply save the lives of vast numbers of hypoxic newborns (“blue babies”)and prevent or reverse pulmonary hypertension in hundreds of thousands of adults during surgery…